治疗卵巢癌的铂类药物耐药机制的研究进展
作者：谢聪;尹如铁;杨开选;
Author：
收稿日期： 年卷（期）页码：2011,26(03):-291-293
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：卵巢癌;化疗;铂耐药;综述
Key words：
基金项目：
中文摘要
综述了有关卵巢癌铂类药物耐药机制的研究情况及近年来取得的新进展。
参考文献
[1]尹如铁,王丹青,谢聪,等.奥沙利铂左卵巢癌治疗中的研究进展[J].华西药学杂志,2009,14(4):433-436.
[2]Steffensen KD,Waldstrm M,Jakobsen A.The relationship ofplatinum resistance and ERCC1 protein expression in epithelial o-varian cancer[J].Int J Gynecol Can,2009,19(5):820-825.
[3]Ferry KV,Hamilton TC,Johnson SW.Increased nucleotide exci-sion repair in cisplatin-resistant ovarian cancer cells:role of ER-CC1-XPF[J].Biochem Pharmacol,2000,60(9):1305-1313.
[4]Selvakumaran M,Pisarcik DA,Bao R,et al.Enhanced cisplatincytotoxicity by disturbing the nucleotide excision repair pathwayin ovarian cancer cell lines[J].Can Res,2003,63(6):1311-1316.
[5]Wataru Sakai,ElizabethM Swisher,Beth Y Karlan,et al.Seconda-ry mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers[J].Nature,2008,451:1116-1120.
[6]Fong PC,Yap TA,Boss DS,et al.Poly(ADP)-ribose polymer-ase inhibition:frequent durable responses in BRCA carrier ovariancancer correlating with platinum-free interval[J].J Clin Oncol.2010,28(15):2512-2519.
[7]Cohen C,Lohmann CM,Cotsonis G,et al.Survivin expression inovarian carcinoma:Correlation with apoptotic markers and prog-nosis[J].Mod Pathol,2003,16(6):574-583.
[8]Wang Z,Xie Y,Wang H.Changes in survivin messenger RNAlevel during chemotherapy treatment in ovarian cancer cells[J].Cancer B iology&Therapy,2005,4(7):716-719.
[9]张欣,李宁,王益华,等.RNA干扰survivin基因对卵巢癌细胞生长凋亡及药物敏感性的影响[J].中华肿瘤杂志,2009,31(3):174-177.
[10]Zisowsky J,Koegel S,Leyers S,et al.Relevance of drug uptakeand efflux for cisplatin sensitivity of tumor cells[J].BiochemPharmacol,2007,73:298-307.
[11]Holzer AK,Samimi G,Katano K,et al.The copper influx trans-porter human copper transport protein 1 regulates the uptake ofcisplatin in human ovarian carcinoma cells[J].Mol Pharmacol,2004,66:817-823.
[12]Noordhuis P,Laan AC,van de Born K,et al.Oxaliplatin activityin selected and unselected human ovarian and colorectal cancercell lines[J].Biochem Pharmacol,2008,76:53-61.
[13]Pasquini L,Petronelli A,Petrucci E,et al.Primary ovarian cancercells are sensitive to the proaptotic effects of proteasome inhibitors[J].Int J Oncol,2010,36(3):707-713.
[14]Jandial DD,Farshchi-Heydari S,Larson CA,et al.Enhanced de-livery of cisplatin to intraperitoneal ovarian carcinomas mediatedby the effects of bortezomib on the human copper transporter 1[J].Clin Cancer Res,2009,15(2):553-560.
[15]Ramirez PT,Landen CN Jr,Coleman RL,et al.Phase I trial of theproteasome inhibitor bortezomib in combination with carboplatinin patients with platinum-and taxane-resistant ovarian cancer[J].Gynecol Oncol,2008,108(1):68-71.
[16]Nakayama K,Kanzaki A,Terada K,et al.Prognostic value of theCu-transporting ATPase in ovarian carcinoma patients receivingcisplatin-based chemotherapy[J].Clin Cancer Res,2004,10(8):2804-2811.
[17]Mangala LS,Zuzel V,Schmandt R,et al.Therapeutic targeting ofATP7B in ovarian carcinoma[J].Clin Canc Res,2009,15:3770-3780.
[18]徐伟,陈建利,张佳荣,等.ATP7B基因反义寡核苷酸对卵巢癌SKOV3ipl细胞顺铂敏感性的影响[J].肿瘤,2006,26(1):28-31.
[19]Krasznai ZT,Friedlander E,NagyA,et al.Quantitative and func-tional assay of MDR1/P170-mediated MDR in ascites cells ofpatients with ovarian cancer[J].Anticancer Res,2005,25(2A):1187-1192.
[20]Surowiak P,Materna V,Kaplenko I,et al.Augmented expressionof metallothionein and glutathione S-transferase pi as unfavour-abl prognostic factors in cisplatin-treated ovarian cancer patients[J].Virchows Arch,2005,447(3):626-633.
[21]Beeghly A,Katsaros D,Chen H,et al.Glutathione S-transferasepolymorphisms and ovarian cancer treatment and survival[J].Gy-necol Oncol,2006,100(2):330-337.
[22]Meads MB,Gatenby RA,Dalton WS.Environment-mediateddrug resistance:a major contributor to minimal residual disease[J].Nat Rev Can,2009,9:665-674.
[23]Pan S,Cheng L,White JT,et al.Quantitative proteomics analysisintegrated with microarray data reveals that extracellular matrixproteins,catenins,and p53 binding protein 1 are important forchemotherapy response in ovarian cancers[J].OMICS,2009,13:345-354.
[24]Melvik JE,Dornish JM,Pettersen EO.The binding of cisdichloro-diammineplatinum(Ⅱ)to extracellular and intracellular com-pounds in relation to drug uptake and cytotoxicity in vitro[J].BrJ Can,1992,66:260-265.
[25]Kozin SV,Shkarin P,Gerweck LE.The cell transmembrane pHgradient in tumors enhances cytotoxicity of specific weak acidchemotherapeutics[J].Can Res,2001,61:4740-4743.
【关闭】
